Loading...
•
Jun 30, 2024
MannKind Q2 2024 Earnings Report
MannKind reported a ninth consecutive quarter of revenue growth, driven by increased sales of Tyvaso DPI and Afrezza and advanced two orphan lung programs to human studies.
Key Takeaways
MannKind Corporation reported total revenues of $72 million for Q2 2024, a 49% increase compared to Q2 2023. The company is approaching an annual revenue run rate of over $275 million based on the first half of 2024.
Total revenues reached $72 million, a 49% increase compared to Q2 2023.
Royalties from collaboration increased by 34% due to increased sales of Tyvaso DPI.
Revenue from collaborations and services increased by 132% primarily due to increased manufacturing activities for Tyvaso DPI.
Afrezza net revenue increased by 20% due to price adjustments and higher demand.
Revenue by Segment
Forward Guidance
MannKind is focused on advancing its pipeline, driving in-line growth, and reducing debt to deliver sustainable value.
Positive Outlook
- Advancing orphan lung programs to human studies (Phase 1 and Phase 3).
- MNKD-101 Phase 3 clinical trial activities initiated.
- MNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024.
- Afrezza INHALE-1 pediatric phase 3 clinical trial primary endpoint analysis expected in 4Q 2024.
- Full results from Afrezza INHALE-1 pediatric phase 3 clinical trial expected in 1H 2025.
Challenges Ahead
- Risks associated with manufacturing and supply.
- Risks associated with developing product candidates.
- Risks and uncertainties related to unforeseen delays that may impact the timing of progressing clinical trials and reporting data.
- Risks associated with safety and other complications of our products and product candidates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...